Dianthus Therapeutics Q1 net loss widens on higher expenses

Dianthus Therapeutics

05/05/2026 21:08

Overview

US biotech firm reported Q1 net loss widened yr/yr on higher R&D and G&A expenses

Company raised $719 mln in public offering, ending Q1 with about $1.2 bln cash

Early GO decision reached in CAPTIVATE trial for claseprubart in CIDP

Outlook

Company expects to initiate Phase 3 claseprubart trial in gMG in mid-2026, with results in 2H’28

Top-line results from Phase 2 MoMeNtum trial in MMN expected in Q4’26

Phase 1 healthy volunteer data for DNTH212 anticipated in 2H’26

Result Drivers

HIGHER CLINICAL COSTS - Co said increased R&D expenses were mainly due to higher clinical costs and expanded headcount for claseprubart Phase 2 and 3 development

INCREASED STAFFING - Co said higher G&A expenses reflected increased headcount

Company press release: ID:nGNX1dm8B6

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$40.83 mln
Q1 Income From Operations
-$46.53 mln
Q1 Operating Expenses
$47 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Dianthus Therapeutics Inc is $124.00, about 38.8% above its May 4 closing price of $89.34

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)